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Objectives: To study in relapsing–remitting (RR) multiple sclerosis (MS) whether exacerbations and brain
activity as measured by magnetic resonance imaging (MRI) are associated with plasma levels of anti-
Epstein Barr (EBV) antibodies and EBV DNA.
Methods: This was a prospective study with 73 RR MS patients followed for an average of 1.7 years with
frequent neurological examination and blood sampling. Antibodies to various EBV proteins were
measured by ELISA and plasma EBV DNA was measured by PCR.
Results: All MS patients had IgG antibodies to EBV (viral capsid antigen (VCA) and/or EBV nuclear
antigen (EBNA)), irrespective whether samples were taken at stable disease or exacerbation. A
significantly elevated percentage of the patients (48%) had antibodies against EBV antigens (early antigen,
EA) that indicate active viral replication, compared with the age matched healthy controls (25%).
Antibodies against a control herpesvirus, cytomegalovirus, were similar between the two groups. The
percentage of EA positive individuals and EA titres did not differ between stable disease or exacerbation.
Anti-VCA IgM was positive in three cases, unrelated to disease activity. Using a highly sensitive PCR on 51
samples taken at exacerbation visits, only three patients were found to have one timepoint with viraemia,
and this viraemia was unrelated to disease activity. Of special note was the fact that anti-EA seropositive
patients remained seropositive during follow up, with stable titres over time. We hypothesised that these
patients may constitute a subgroup with higher disease activity, due to the triggering effect of a chronic
attempt of the virus to reactivate. The EA positive group did not differ from the EA negative with respect to
clinical disease activity or other characteristics. However, in the EA positive group, analysis with
gadolinium enhanced MRI indicated more MRI disease activity.
Conclusions: There was no evidence for increased clinical disease activity in the subgroup of MS patients
with serological signs of EBV reactivation. However, the observation that chronic EBV reactivation may be
associated with increased inflammatory activity as assessed by gadolinium enhanced MRI lesions should
be reproduced in a larger and independent dataset.
T
here is accumulating indirect evidence for a role of
Epstein-Barr virus (EBV) infections in the pathogenesis
of multiple sclerosis (MS).1–4 The risk for MS is
significantly increased after infectious mononucleosis, and
MS is rare among individuals without serum anti-EBV
antibodies. Moreover, a recent large prospective epidemiolo-
gical study showed that serum antibody titres against EBV
were increased before onset of MS.5 6 In addition, T cell
reactivity to EBV epitopes is different in MS,7 and in the
cerebrospinal fluid, T cells of MS patients recognise EBV
transformed B cells.8 It may be the age at primary EBV
infection that influences the risk for future development of
MS, analogous to the relation between EBV infection and
development of infectious mononucleosis.9 10
Apart from these studies aiming at the aetiology of MS,
studies that investigate the relation between EBV and
MS disease activity are scarce. The striking property of
herpesviruses such as EBV to show periodic reactivation
makes EBV an attractive candidate as a co-factor in the
relapsing remitting course of MS. It has been suggested that
EBV reactivation is associated with the occurrence of
exacerbations.11 Recently, we conducted a prospective study
to investigate the role between infections and exacerba-
tions in MS. Using the material obtained during that
study, we questioned whether EBV antibody and EBV
DNA levels in plasma are increased during exacerbations in
MS and whether serological signs of EBV activity correlate
with activity measured by magnetic resonance imaging
(MRI).
METHODS
Patients and samples
Data and material for this study were collected in the
Rotterdam Study on Exacerbations in MS (ROSE), a
prospective cohort study specifically designed to investigate
the relation between MS exacerbations and infections.12
Patients with relapsing–remitting (RR) MS were followed
for a mean of 1.7 years. EDSS scores were performed at
regular 8 week visits and at two additional visits (3 weeks
apart) in case of either exacerbation or clinical infection,
when also blood samples were collected.
In a random subgroup, a series of three magnetic
resonance imaging (MRI) examinations were planned
following every infection over a period of 6–7 weeks after
the onset of infection. In addition, control plasma samples
were collected from healthy individuals (n=52). All plasma
samples were immediately frozen in 280 C˚ until use.
Definitions
Exacerbation was defined as worsening of existing or
appearance of new symptoms lasting more than 24 hours
and following a period of at least 30 days of improvement or
stability.13 Neurological deterioration only temporarily asso-
ciated with a period of fever was not considered as
exacerbation. Infection was defined as the appearance of
Abbreviations: EA, early antigen; EBNA, Epstein-Barr nuclear antigen;
EBV, Epstein-Barr virus; MS, multiple sclerosis; RR, relapsing–remitting;
VCA, viral capsid antigen
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coryza, sore throat, flu-like feeling, myalgia, fever, diarrhoea,
or a urinary infection lasting for more than 24 hours.
Exacerbations were categorised according to severity and
duration. Exacerbations with an EDSS increase >1.0 and
lasting more than 3 months were defined as sustained
progression.12
Detection of viral antibodies
The following antibodies to Epstein-Barr antigens were
determined: IgM and IgG against EBV viral capsid antigen
(VCA), IgG against EBV early antigen (EA) and IgG against
Epstein-Barr nuclear antigen (EBNA).14 Antibodies to these
antigens were determined by ELISA (Biotest, Dreieich,
Germany) following the manufacturer’s instructions. Anti-
cytomegalovirus (CMV) IgG was tested with ELISA (ETI-
Cytok G; Diasorin, Saluggia, Italy).
For each measurement of an antibody concentration, a
ratio was calculated as sample optical density (OD) value
divided by cutoff OD value. The cutoff values were defined as
the mean OD+3SD of the negative control. For all assays, a
ratio of .2.0 was considered as seropositive.
PCR
Taqman PCR primers were selected from the EBV DNA
genome encoding for the non-glycosylated membrane protein
BNRF1 P143, and generated a DNBA product of 74 bp.15 A
known EBV copy number based on a reference standard
quantified by electron microscopy (ABI Advanced
Biotechnologies, Columbia, MS, USA) was used for standard-
isation. Serial dilutions ranging from 10 to 107 genome
equivalents per ml (gEq/ml) were made to characterise
linearity, precision, specificity, and sensitivity. The Taqman
assay appeared to detect viral DNA in plasma over a linear
span between 50 and 107 gEq/ml with an average coefficient
of variation of 1.56% (range 0.7 to 7.0%). Test results below
50 gEq/ml were considered negative. No viral DNA was
detected in plasma of healthy EBV seropositive individuals.
Magnetic resonance imaging protocol
In case of symptomatic infection, a series of three MRI scans
was planned in a random subset of patients: the first soon
after the onset of infection (MRI1); the second after a period
of 3 weeks (MRI2), and the third after 6 weeks (MRI3),12
using a 1.5 T imaging unit (Philips Gyroscan ACS-NT).
Initially, 5 mm slices from T1 weighted sequences were
obtained using 0.1 mmol/kg gadolinium diethylene triamine
penta-acetate (Gd-DTPA; single dose). Halfway through the
study, 0.3 mmol/kg Gd-DTPA (triple dose) with 3 mm slice
protocol was applied to enhance sensitivity.12 We quantified
the number of Gd enhanced lesions, the number of new
lesions in the second and third MRIs of the same series
and the number and percentage of active MRI series per
patient. An active MRI series was defined as a series with at
least one enhanced lesion in any of the three MRIs. Only
scans of patients not treated with interferon (IFN)-b were
analysed.
Statistics
Between group differences in different demographic, MRI,
and serological parameters (ratios) were analysed by inde-
pendent t tests or Mann-Whitney test. Difference in mean
EDSS value was tested using the Mann-Whitney test.
Frequency distribution between groups for number of
patients with sustained progression and for sex, number,
and type of exacerbations were tested by x2 test. Comparison
of different MRI parameters between groups was performed
using Mann-Whitney or Fisher’s exact test.
RESULTS
Clinical characteristics
Of 73 patients, 58 had at least one exacerbation during study
follow up and were selected for further analysis. Plasma
samples from 54 of the 58 patients were available for
analysis. Average age was 39.3 years, with average disease
duration of 10.4 years, and an average baseline EDSS of 2.5
(median 2.0, range 0 to 6.0). The total follow up time was
5130 weeks (98.7 years), during which 141 exacerbations
occurred.
EBV seropositivity
As markers of previous EBV infection, anti-VCA IgG and anti-
EBNA IgG were tested in 54 patients (total 188 samples).
Anti-VCA IgG was positive in each sample of all 54 patients
(100%) and anti-EBNA IgG in 51 of 54 patients (94%). We
tested anti-VCA IgM and anti-EA IgGA as markers for
reactivation of EBV.16 17 All 188 samples tested for anti-VCA
IgM were negative except three, collected on a single occasion
in three different patients. IgG seropositivity to EA was tested
in 214 samples from 54 patients (average 3.9 samples per
patient, median 3, range 2 to 18). Anti-EBV EA IgG was
positive in 26 of 54 (48%) of the patients (table 1).
Because others previously reported a difference in anti-EA
positivity between MS patients and healthy individuals,18 19
we also tested anti-EA IgG in a group of 52 age matched
healthy individuals. Significantly fewer of these controls
were positive (13/52, 25%, p=0.013). In addition, the
concentrations of anti-EA IgG were significantly higher in
the MS group (median 1.8, mean (SD) 2.2 (0.2)) than in the
healthy controls (0.6, 1.3 (0.2), p,0.001; Mann-Whitney U
test, fig 1). Differences remained after exclusion of patients
that received IFN-b. IgG titres against the control herpes-
virus, CMV did not differ significantly between MS patients
and healthy individuals. In the MS group, 44% were anti-
CMV IgG positive versus 56% in the healthy controls
(p=0.2).
Exacerbations and EBV seropositivity
We analysed if the occurrence of exacerbations was asso-
ciated with a higher percentage in EBV seropositivity. We
compared samples collected at the baseline visits (when there
was no exacerbation and/or infection) with samples taken
during the first exacerbation. Exacerbation samples were
collected at the second exacerbation related visit, 3 weeks
after the onset of exacerbation, to allow sufficient time for
development of a titre increase. In total, 45 paired baseline
exacerbation samples were available. Anti-VCA IgG was
positive in 100% of cases, at both timepoints. None of the
samples was positive for anti-VCA IgM, either at the baseline
or at exacerbations. Anti-EBNA IgG was positive in 43/45
patients, both at baseline and exacerbation visits. Anti-EA
IgG were positive in 24 of 45 baseline (53%) and in 22 of 45
Table 1 Frequency of seropositivity for
different anti-EBV antibodies in the study
population*
Anti-
VCA
IgG
Anti-
EBNA
IgG
Anti-
EA
IgG
No. of
patients
+ + + 24
+ + – 27
+ – + 2
+ – – 1
Total 54
*Based on the measurement of at least two different plasma
samples taken per patient (total 188 samples for anti-VCA
and anti-EBNA and 214 samples for anti-EA).
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exacerbation samples (49%) (p=0.7). Thus, no significant
difference in EBV seropositivity was found between baseline
and exacerbation samples.
Titres of anti-EBV IgG and exacerbations
To examine whether exacerbations in MS are associated with
a change in anti-EA IgG ratio, we performed a quantitative
analysis in the same set of 45 baseline–exacerbation paired
samples. The mean (SD) anti-EA IgG ratio was 2.4 (0.3) at
baseline, compared with 2.3 (0.3) at exacerbation (p=0.2,
paired t test, fig 2). Therefore, exacerbations were not found
to be associated with a change in anti-EA Ig titre.
Anti-EA IgG ratios: a stable phenomenon
Anti-EA IgG antibodies have been described to fluctuate over
time, in association with EBV reactivation.11 We were
surprised to observe that nearly all patients who tested EA
positive at one timepoint remained positive at all other
timepoints tested. A total of 214 samples from 54 patients
was tested for EA-IgG positivity (average 3.9 samples per
patient, median 3, range 2 to 18) covering a period of
1537 weeks or 30% of follow up time (on average 28.5 weeks
per patient, median 19, range 2 to 104). Levels of anti-EBV
EA IgG remained remarkably stable within individual
patients (intraclass correlation (ICC)=0.96) (fig 3).
Anti-EA IgG positive and negative individuals:
different clinical characteristics
In total, 26 patients were EA seropositive (mean (SD) ratio
3.7 (0.1)) and 28 seronegative (1.1 (0.2)). Testing the
samples of these groups for IgG titres against control viruses
(HHV6, CMV, and parainfluenza 1) revealed no significant
titre differences between the EA seropositive group (EA+)
and EA negative group (EA2) groups (p.0.2, data not
shown). Furthermore, the levels of the IgG EA titres did not
show any correlation with the IgG titres against these control
viruses, which makes it unlikely that EA seropositivity was
merely part of a more generalised aspecific immune activa-
tion.
Because of the stable anti-EA IgG positivity over time, we
were interested whether the EA+ group had intrinsic clinical
characteristics that were different from the EA2. Baseline
demographic data for these two groups are given in table 2,
showing no significant differences between the two groups in
sex, age, disease duration, or progression up to the start of
the study.
Clinical features observed during follow up were also
similar between EA+ and EA2 patients. EA+ patients were
followed for 47.9 years with 60 exacerbations, 13 of which
were sustained, while EA2 patients were followed up for
49.2 years with 80 exacerbations, 15 of which were sustained.
In both groups, 13 patients had at least one exacerbation
with sustained progression. Mean annual relapse rate was 1.4
in the EA+ and 1.8 in the EA2 group (p=0.1, Mann-
Whitney). Mean annual relapse rate for exacerbations with
sustained progression was 0.28 in the EA+ and 0.27 in the
EA2 group (p=0.96, Mann-Whitney). Disease progression
rate (in EDSS points; mean (SE)) during the follow up also
did not differ between the groups (EA+ patients 0.5 (0.2),
EA2 patients 0.6 (0.3), p=0.96 Mann-Whitney).
More conservative calculation, using only clinical data
from the follow up period between samples (that is, from the
first to the last samples per patient) gave similar results
(table 2). The total follow up in this calculation was
29.6 years, with 66 exacerbations, 15 of which were exacer-
bations with sustained progression. Mean annual exacerba-
tion rate and exacerbation rate for exacerbations with
sustained progression again did not differ between the two
groups. In the EA+ group, median annual RR was 3.0 (3.3
(0.4), and in the EA2 group 2.6 (mean (SE) 3.2 (0.5),
p=0.4, Mann-Whitney). For exacerbations with sustained
progression the median annual exacerbation rate in the EA+
group was 0.0 (1.2 (0.5), and in the EA2 group 0.0 (mean
(SE) 0.4 (0.2)), p=0.3, Mann-Whitney). We were thus
unable to detect any difference in the clinical course of MS
between these two groups.
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Figure 1 Anti-EBV EA IgG ratio in MS patients (n = 54) and age
matched healthy controls (n = 52). Boxplot represents interquartile range
including 50% of the values. Line across the boxplot represents median.
Whiskers extend to the highest and lowest value, excluding outliers,
which are given separately. Mean (SE) anti-EBV EA was 2.2 (0.2) in the
MS group and 1.3 (0.2) in the healthy controls, p,0.001. Dotted line
represents the cutoff value.
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Figure 2 The scatterplot representing anti-EBV EA IgG ratio at the
baseline and at the first exacerbation, n = 45. Dotted line represents the
line of identity.
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Figure 3 Stability of anti-EBV EA IgG titre during follow up. The y axis
depicts anti-EBV EA ratio for each sample. Individual patients, sorted on
mean EA ratio from lowest to highest (n = 54), are represented along the
X-axis. Filled squares represent samples taken during exacerbation.
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EBV antigenaemia and exacerbations
Because of the serological indication of a high percentage of
EBV reactivation, we used an ultrasensitive PCR to test for
the presence of EBV antigen in 51 samples drawn during the
exacerbation visits of 48 patients. Only 3 of 51 samples (6%)
were positive. From these three patients we performed the
PCR analysis in all samples that were obtained during study
follow up; 17 samples per patient (a total of 51). None tested
positive.
MRI lesions and EA serology
A series of three sequential MRI scans from 37 patients
without immunomodulatory treatment was available for
analysis. The time lapse between the onset of infection and
the MRI recordings was 7, 24, and 47 days for the first,
second, and third MRI respectively.12 We performed the
analysis separately for single and triple Gd MRIs.
In the Gd single dose group, a series from 12 EA+ and 15
EA2 and patients was available, and in the triple dose group,
a series from 9 EA+ and 11 EA2 patients was available. The
results are shown in table 3. In both single and triple Gd
series we observed more MRI activity in the EA+ group. These
patients had on average more Gd enhanced lesions, more
new lesions, and a more active MRI series. This difference
showed a trend in the single Gd MRI series, and reached
statistically significant levels in the triple Gd MRI series.
DISCUSSION
This study confirms earlier reports that 100% of the MS
patients have serological signs of a previous EBV infection,1 20
and that a disproportionally high percentage of MS patients
have elevated titres of anti-EA antibodies.18 19 The presence of
anti-EA antibodies indicates acute or chronic active EBV
infection and onset of viral replication.16 17 There are
indications that the primary EBV infection in MS patients
has occurred years before the onset of neurological symp-
toms,9–11 20 with a possible risk enhanced role for primary
infections occurring relatively later in life (adolescence).10 21 A
remarkable finding of this study was the fact that during
follow up, EA seropositivity remained stable over time.
Normally, EA titres decline within weeks or months after a
primary infection or a reactivation of EBV.16 17 Therefore, we
investigated whether these patients had active viral replica-
tion, resulting in continuous viraemia. However, with a
highly sensitive PCR, we could only detect viraemia at three
timepoints, and this was found to be transient. How can the
findings of elevated immune responses against an early lytic
EBV protein, but a lack of viraemia be reconciled? Chronic T
cell responses against EBV proteins of the early replication
phase, such as EA and polymerases, can prevent viral
replication and shedding.22 24 In this respect it is of extra
interest that the EA associated DNA polymerase bears a
mimicry motif for myelin basic protein reactive T cell
clones.25–28
We observed no relation between increased EA titres or
viraemia on the one hand and exacerbations or clinical
phenotype on the other. Recently, Wandinger et al reported
some indications for relatively more active EBV replication in
a subgroup of 11 MS patients with clinical exacerbations
than in eight clinically stable patients.11 What could account
for the discrepancy between the two studies? There were
technical differences, such as the use of a different PCR and
the lack of IgA serology in our study. In the Wandinger study,
significance was only reached after making a composite score
of several serological tests together with PCR. Furthermore,
we specifically selected samples taken during exacerbation
for PCR analysis, whereas Wandinger considered time
windows up to 12 months around exacerbations.
A particular aspect of our study was the possibility of
analysing the association between EA seropositivity and MRI
activity. We observed higher numbers of gadolinium
enhanced lesions in the EA+ than in the EA2 group, both
on single and triple dose scans. In the single dose Gd group,
with relatively lower sensitivity to detect lesions, a trend was
observed. In triple dose Gd series, 89% of EA+ patients had at
least one active MRI series and a significantly higher mean
number of gadolinium enhanced lesions. These findings
could perhaps be seen as a reflection of a higher rate of
lesional activity in the EA+ group.
As there are many recordings of elevated antibody
production against a variety of antigens in MS,29 it could be
argued that the observed enhanced anti-EA production is
merely part of a non-specific polyclonal B cell response. In
this light, elevated production of EA antibodies would simply
be related to a higher active state of the immune system, thus
associated with more inflammation in the brain. However,
Table 2 Clinical characteristics of patients in EBV EA
seropositive and negative groups
Mean anti-EBV EA IgG ratio
.2.0 (EA+) ,2.0 (EA2)
Demographic data
No. of patients (F/M) 26 (22/4) 28 (20/8)
Mean (SE) age in years 41.3 (1.5) 37.3 (2.0)
Mean (SE) disease
duration in years
10.7 (1.2) 10.0 (1.4)
Mean baseline EDSS
(median, range)
2.3
(2.0, 0 to 5.5)
2.7
(2.0, 0 to 6.0)
Annual progression rate
of disease (SE)
0.3 (0.1) 0.4 (0.2)
Study data*
Years of follow up 11.4 18.2
No. of exacerbations 28 38
Median (mean) (SE)
annual exacerbation rate
3.0 (3.3) (0.4) 2.6 (3.2) (0.5)
No. of exacerbations with
sustained progression`
8 7
Median annual
exacerbation rate for
exacerbations with
sustained progression
(mean (SE))
0.0 (1.2) (0.5) 0.0 (0.4) (0.2)
*Follow up data presented here relate only to the follow up period from
the first to the last collected sample per patient, which is shorter than
clinical follow up per patient; calculated as baseline EDSS per number
of years since disease onset; `for definition of sustained progression, see
text.
Table 3 MRI data for EA+ and EA2 patients
Mean anti-EBV EA IgG
ratio
p value,2.0 (EA2) .2.0 (EA+)
1-Gd
Number of patients 15 12
Mean no. of Gd enhanced
lesions
0.14 (0.07 0.7 (0.5 0.3
Mean no. of new lesions 0.05 (0.05 0.3 (0.2 0.09
No. of patients (%) with >1
active MRI series
4 (27%) 5 (42%) 0.4*
3-Gd
Number of patients 11 9
Mean no. of Gd enhanced
lesions
0.39 (0.2 1.87 (0.8 0.03
Mean no. of new lesions 0.05 (0.05 0.48 (0.3 0.02
No. of patients (%) with >1
active MRI series
5 (45%) 8 (89%) 0.07*
One MRI series per patient was analysed;, lesion numbers are depicted
as mean (SEM). All calculations Mann-Whitney except for *Fisher’s exact
test.
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antibody production against other control viruses was not
heightened in the EA seropositive group. Although we did
not observe a higher clinical exacerbation rate in EA
seropositive MS patients, it cannot be ruled out that EBV
reactivation is related to lesion activity as detected by MRI.
This could be of interest, because MRI is more sensitive in
recording the occurrence of new lesions. However, this study
was not powered to investigate a relationship between anti-
EA titre status and MRI activity. This preliminary observation
should thus be reproduced in a larger dataset before drawing
firm conclusions.
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